These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 9499797)
41. Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. Pizzato M; Helander A; Popova E; Calistri A; Zamborlini A; Palù G; Göttlinger HG Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6812-7. PubMed ID: 17412836 [TBL] [Abstract][Full Text] [Related]
42. Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells. Tobiume M; Lineberger JE; Lundquist CA; Miller MD; Aiken C J Virol; 2003 Oct; 77(19):10645-50. PubMed ID: 12970449 [TBL] [Abstract][Full Text] [Related]
43. The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity. Chen YL; Trono D; Camaur D J Virol; 1998 Apr; 72(4):3178-84. PubMed ID: 9525644 [TBL] [Abstract][Full Text] [Related]
44. Cell-dependent functional roles of HIV-1 Nef for virus replication (review). Adachi A; Oshima Y Int J Mol Med; 1999 Apr; 3(4):427-30. PubMed ID: 10085418 [TBL] [Abstract][Full Text] [Related]
45. Influence of Different Glycoproteins and of the Virion Core on SERINC5 Antiviral Activity. Diehl WE; Guney MH; Vanzo T; Kyawe PP; White JM; Pizzato M; Luban J Viruses; 2021 Jun; 13(7):. PubMed ID: 34209034 [TBL] [Abstract][Full Text] [Related]
46. Folimycin (concanamycin A), an inhibitor of V-type H(+)-ATPase, blocks cell-surface expression of virus-envelope glycoproteins. Muroi M; Takasu A; Yamasaki M; Takatsuki A Biochem Biophys Res Commun; 1993 Jun; 193(3):999-1005. PubMed ID: 8391816 [TBL] [Abstract][Full Text] [Related]
47. Vesicular stomatitis virus G protein acquires pH-independent fusion activity during transport in a polarized endometrial cell line. Roberts PC; Kipperman T; Compans RW J Virol; 1999 Dec; 73(12):10447-57. PubMed ID: 10559363 [TBL] [Abstract][Full Text] [Related]
48. Association of Nef with the human immunodeficiency virus type 1 core. Kotov A; Zhou J; Flicker P; Aiken C J Virol; 1999 Oct; 73(10):8824-30. PubMed ID: 10482638 [TBL] [Abstract][Full Text] [Related]
56. Influence of endosome-destabilizing peptides on efficacy of anti-HIV immunotoxins. Tolstikov VV; Cole R; Fang H; Pincus SH Bioconjug Chem; 1997; 8(1):38-43. PubMed ID: 9026033 [TBL] [Abstract][Full Text] [Related]
57. Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. Whitt MA J Virol Methods; 2010 Nov; 169(2):365-74. PubMed ID: 20709108 [TBL] [Abstract][Full Text] [Related]
58. Development of Zika Virus E Variants for Pseudotyping Retroviral Vectors Targeting Glioblastoma Cells. Grunwald V; Ngo HD; Formanski JP; Jonas JS; Pöhlking C; Schwalbe B; Schreiber M Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833934 [TBL] [Abstract][Full Text] [Related]